Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients

This study has been completed.
Sponsor:
Collaborators:
Synteract, Inc.
Cystic Fibrosis Foundation Therapeutics
Information provided by (Responsible Party):
Savara Inc.
ClinicalTrials.gov Identifier:
NCT01746095
First received: December 6, 2012
Last updated: December 5, 2014
Last verified: December 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2014
  Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)